224 related articles for article (PubMed ID: 37364935)
1. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
[TBL] [Abstract][Full Text] [Related]
2. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
Jeong S; Park E; Kim HD; Sung E; Kim H; Jeon J; Kim Y; Jung UJ; Son YG; Hong Y; Lee H; Lee S; Lim Y; Won J; Jeon M; Hwang S; Fang L; Jiang W; Wang Z; Shin EC; Park SH; Jung J
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230109
[TBL] [Abstract][Full Text] [Related]
3. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors.
Xu G; Qian N; Liu Y; Li H; Yang C; Wang J; Wang F; Chen L; Bai G; Xu Q; Pan X; Gao X
Immunobiology; 2022 Nov; 227(6):152283. PubMed ID: 36198215
[TBL] [Abstract][Full Text] [Related]
5. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
6. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
7. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.
Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B
Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978
[TBL] [Abstract][Full Text] [Related]
8. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.
Yue J; Shao S; Zhou J; Luo W; Xu Y; Zhang Q; Jiang J; Zhu MM
Invest New Drugs; 2024 Feb; 42(1):106-115. PubMed ID: 38198061
[TBL] [Abstract][Full Text] [Related]
9. ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.
Konno H; Lin T; Wu R; Dai X; Li S; Wang G; Chen M; Li W; Wang L; Sun BC; Luo Z; Huang T; Chen Y; Zhang J; Ye Q; Bellovin D; Wan B; Kang L; Szeto C; Hsu K; Kabbarah O
Cancer Res Commun; 2022 Sep; 2(9):937-950. PubMed ID: 36922936
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.
Hinner MJ; Aiba RSB; Jaquin TJ; Berger S; Dürr MC; Schlosser C; Allersdorfer A; Wiedenmann A; Matschiner G; Schüler J; Moebius U; Rothe C; Matis L; Olwill SA
Clin Cancer Res; 2019 Oct; 25(19):5878-5889. PubMed ID: 31138587
[TBL] [Abstract][Full Text] [Related]
11. The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Nelson MH; Fritzell S; Miller R; Werchau D; Van Citters D; Nilsson A; Misher L; Ljung L; Bader R; Deronic A; Chunyk AG; Schultz L; Varas LA; Rose N; Håkansson M; Gross J; Furebring C; Pavlik P; Sundstedt A; Veitonmäki N; Ramos HJ; Säll A; Dahlman A; Bienvenue D; von Schantz L; McMahan CJ; Askmyr M; Hernandez-Hoyos G; Ellmark P
Mol Cancer Ther; 2023 Jan; 22(1):89-101. PubMed ID: 36343381
[TBL] [Abstract][Full Text] [Related]
12. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
13. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
[TBL] [Abstract][Full Text] [Related]
14. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
[TBL] [Abstract][Full Text] [Related]
15. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
[TBL] [Abstract][Full Text] [Related]
16. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
[TBL] [Abstract][Full Text] [Related]
17. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
[TBL] [Abstract][Full Text] [Related]
18. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
Zhai T; Wang C; Xu Y; Huang W; Yuan Z; Wang T; Dai S; Peng S; Pang T; Jiang W; Huang Y; Zou Y; Xu Y; Sun J; Gong X; Zhang J; Tsun A; Li B; Miao X
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172514
[TBL] [Abstract][Full Text] [Related]
19. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
[TBL] [Abstract][Full Text] [Related]
20. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
